Nautilus Biotechnology, Inc.
NAUT· Nasdaq
NAUTNautilus Biotechnology, Inc.
Filed Nov 2, 2021 · 10-Q · 33 days after period end · 0001808805-21-000019
| Metric | Q3 2021 | Q3 2020 |
|---|---|---|
| Net Income | -$14.50M | -$3.98M |
| EPS Diluted | -$0.12 | -$0.13 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nautilus Biotechnology, Inc. · CIK 1808805 · Engraved from SEC EDGAR
ended Sep 30, 2021 · filed Nov 2, 2021 · 33 d after period end
